STOCK TITAN

HeartSciences may offer up to $3.08M in common stock

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

HeartSciences Inc. may offer common stock in an at-the-market offering for up to $3,077,649 in aggregate offering price under the current prospectus supplement. The Equity Distribution Agreement with Maxim Group LLC permits up to $50,000,000 in sales, included within the $200,000,000 base shelf. While the aggregate market value of the company’s voting and non-voting common shares held by non-affiliates is below $75 million, Form S-3 Instruction I.B.6 limits public primary sales to one-third of that value in any 12-month period.

After a placement notice, Maxim will use commercially reasonable efforts to sell shares under the company’s instructions and agreement conditions, but is not required to buy shares as principal. HeartSciences pays a 2.5% commission while subject to the Form S-3 limit and 2.0% thereafter, plus legal-fee reimbursement up to $15,000 for preparing and entering the agreement and up to $5,000 per Bringdown Date. Either party may terminate on notice; Maxim may also terminate in specified circumstances, including a material adverse change making marketing impractical or inadvisable.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Current prospectus supplement offering amount Up to $3,077,649 aggregate offering price Shares covered by the prospectus supplement
Equity Distribution Agreement ceiling Up to $50,000,000 Included within the $200,000,000 base shelf
Base shelf capacity $200,000,000 Securities that may be offered, issued and sold under the base prospectus
Non-affiliate market value threshold $75 million Form S-3 Instruction I.B.6 limitation applies while non-affiliate market value is below this amount
Commission while subject to Form S-3 I.B.6 2.5% Of gross sales price per share for shares sold through Maxim
Commission after Form S-3 I.B.6 limitation ends 2.0% Of gross sales price per share for shares sold through Maxim
Legal-fee reimbursement Up to $15,000 For preparation and entry into the Equity Distribution Agreement
Bringdown Date expense reimbursement Up to $5,000 per Bringdown Date Reimbursement to Maxim under the agreement
at the market offering financial
"in an “at the market offering”"
An at-the-market offering is a way a company raises cash by selling newly issued shares directly into the open market at prevailing prices, rather than all at once in a single deal. Think of it like turning a faucet on to drip shares into trading at current prices when needed; it gives the company flexibility to raise funds over time but can dilute existing shareholders and potentially affect the stock price, which investors should monitor.
General Instruction I.B.6 of Form S-3 regulatory
"subject to the limitations of General Instruction I.B.6 of Form S-3"
aggregate offering price financial
"Shares having an aggregate offering price of up to $3,077,649"
The aggregate offering price is the total dollar amount that will be raised if all the securities in an offering are sold at the stated offering price, before fees or expenses are taken out. Investors use it to gauge the size of the fundraising and its potential effects—such as how much cash the company will get and how much existing ownership might be reduced—similar to totaling every item’s price in a shopping cart to see the full bill.
placement notice technical
"Upon delivery of a placement notice"
commercially reasonable efforts technical
"use its commercially reasonable efforts"
Offering Type ATM
Securities Offered Common stock, $0.001 par value per share
Offering Amount Up to $3,077,649 aggregate offering price under the prospectus supplement; up to $50,000,000 under the Equity Distribution Agreement

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much can HSCS sell through its ATM offering?

The current prospectus supplement covers up to $3,077,649 in aggregate offering price. The Equity Distribution Agreement permits up to $50,000,000 in sales, an amount included within the $200,000,000 base shelf.

What commission does HSCS pay Maxim for ATM sales?

HeartSciences pays 2.5% while subject to the Form S-3 I.B.6 limitations and 2.0% thereafter, based on the gross sales price per share for shares sold through Maxim. It also reimburses up to $15,000 in legal fees for preparing and entering the agreement and up to $5,000 per Bringdown Date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001468492 0001468492 2026-11-18 2026-11-18 0001468492 us-gaap:CommonStockMember 2026-11-18 2026-11-18 0001468492 HSCS:WarrantsMember 2026-11-18 2026-11-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 18, 2026

 

 

 

HEARTSCIENCES INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Texas   001-41422   26-1344466
(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

550 Reserve Street, Suite 360    
Southlake, Texas   76092
(Address of Principal Executive Offices)   (Zip Code)
     

 

Registrant’s Telephone Number, Including Area Code: (682) 237-7781

 

n/a

(Former Name or Former Address, if Changed Since Last Report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☒Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  Trading Symbol(s)   Name of each exchange on which registered
Common Stock   HSCS   The Nasdaq Stock Market LLC
Warrants   HSCSW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On November 18, 2026, HeartSciences Inc. (the “Company” or “HeartSciences”) entered into an Equity Distribution Agreement (the “EDA”) with Maxim Group LLC (“Maxim Group”) as sales agent, pursuant to which the Company may offer and sell, from time to time, an aggregate of up to $50,000,000 of its shares of common stock, $0.001 par value per share (the “Shares”), in an “at the market offering” (as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the “Securities Act”)).

 

The Shares may be issued and sold from time to time through or to Maxim Group acting as sales agent or principal pursuant to the Company’s shelf Registration Statement on Form S-3, as amended (File No. 333-299147), as declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on November 17, 2026 (the “Registration Statement”). The Company will file a prospectus supplement, dated November 19, 2026, pursuant to Rule 424(b) under the Securities Act with respect to the Shares (the “Prospectus Supplement”). Sales of the Shares, if any, under the Prospectus Supplement may be made in transactions that are deemed to be “at the market offerings” pursuant to Rule 415 under the Securities Act. Pursuant to General Instruction I.B.6 of Form S-3, the Company may not sell the shelf securities in a public primary offering with a value exceeding more than one-third of the aggregate market value of its voting and non-voting common shares held by non-affiliates in any 12-month period as long as the aggregate market value of the Company’s outstanding common shares held by non-affiliates is less than $75 million. Accordingly, although the EDA provides for the sale of up to $50,000,000 of Shares, which amount is included in the $200,000,000 of securities that may be offered, issued and sold by the Company under the base prospectus included in the Registration Statement, the Prospectus Supplement covers the offer and sale of Shares having an aggregate offering price of up to $3,077,649.

 

Under the EDA, Shares may be sold by any method permitted by law deemed to be an “at the market offering.” Maxim Group will also be able to sell Shares by any other method permitted by law, including in negotiated transactions with the Company’s prior written consent. Upon delivery of a placement notice and subject to the terms and conditions of the EDA, Maxim Group is required to use its commercially reasonable efforts consistent with its normal trading and sales practices, applicable state and federal law, rules and regulations, and the rules of The Nasdaq Capital Market to sell the Shares from time to time based upon the Company’s instructions, including any price, time or size limits specified by the Company. Maxim Group is not under any obligation to purchase any of the Shares on a principal basis pursuant to the EDA. Maxim Group’s obligations to sell the Shares under the EDA are subject to satisfaction of certain conditions, including customary closing conditions.

 

The EDA contains representations, warranties and covenants that are customary for transactions of this type. The Company will pay Maxim Group a commission equal to (x) 2.5%, for so long as the Company is subject to the limitations of General Instruction I.B.6 of Form S-3, and (y) 2.0% thereafter, for so long as the Company is not subject to the limitations of General Instruction I.B.6 of Form S-3, if any, of the gross sales price per share for any Shares sold through Maxim Group under the EDA. The Company will also reimburse Maxim Group’s legal fees and expenses up to $15,000 in connection with the preparation and entering into the EDA plus up to $5,000 per Bringdown Date (as defined in the EDA). The Company has provided Maxim Group with customary indemnification and contribution rights. The EDA may be terminated by Maxim Group or the Company at any time upon notice to the other party as provided in the EDA, or by Maxim Group at any time in certain circumstances, including the occurrence of a material and adverse change in the Company’s business or financial condition that makes it impractical or inadvisable to market the Shares or to enforce contracts for the sale of the Shares.

 

This Current Report on Form 8-K (this “Current Report”) shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the Shares in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

 

The foregoing description is a summary only, does not purport to set forth the complete terms of the EDA and is qualified in its entirety by reference to the EDA filed as Exhibit 1.1 to this Current Report and incorporated herein by reference. The legal opinion of Foley Shechter Ablovatskiy LLP, counsel to the Company, relating to the validity of the Shares being offered pursuant to the EDA is filed as Exhibit 5.1 to this Current Report and is incorporated herein by reference.

 

1

 

 

Additional Information and Where to Find It

 

As previously reported, on June 23, 2026, the Company and Fortitude Mining Holdings, Inc. (“Fortitude”), a vertically-integrated digital asset mining platform anchored in Zcash, entered into a definitive merger agreement (as amended, the “Merger Agreement”) to combine in an all-stock transaction (the “Proposed Transaction”). The following is important information that should be read together with this Current Report. 

 

Communications related to each of Fortitude and HeartSciences, their respective businesses and the Proposed Transaction may be deemed solicitation material in respect of the Proposed Transaction. In connection with the Proposed Transaction, on October 19, 2026, HeartSciences filed a definitive proxy statement on Schedule 14A (the “Definitive Proxy Statement”) with the SEC, and has filed and may file additional relevant materials with the SEC from time to time. HeartSciences has mailed the Definitive Proxy Statement and a proxy card to each shareholder entitled to vote at the special meeting relating to the Proposed Transaction. INVESTORS AND SHAREHOLDERS OF HEARTSCIENCES ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE PROPOSED TRANSACTION THAT HEARTSCIENCES HAS FILED OR MAY FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT HEARTSCIENCES AND THE PROPOSED TRANSACTION. COMMUNICATIONS THAT DO NOT CONTAIN ALL THE INFORMATION THAT SHOULD BE CONSIDERED CONCERNING THE PROPOSED TRANSACTION AND RELATED MATTERS ARE NOT INTENDED TO PROVIDE THE BASIS FOR ANY INVESTMENT DECISION OR ANY OTHER DECISION IN RESPECT OF SUCH MATTERS. The Definitive Proxy Statement, the preliminary proxy statement and other relevant materials in connection with the Proposed Transaction (when they become available), and any other documents filed by HeartSciences with the SEC, may be obtained free of charge at the SEC’s website at www.sec.gov. In addition, investors and shareholders may obtain free copies of the documents filed with the SEC or by sending a request to the HeartSciences Investor Relations Department at investorrelations@heartsciences.com.

 

NEITHER THE SEC NOR ANY STATE SECURITIES REGULATORY AGENCY HAS APPROVED OR DISAPPROVED THE TRANSACTIONS DESCRIBED HEREIN, PASSED UPON THE MERITS OR FAIRNESS OF THE PROPOSED TRANSACTION OR ANY RELATED TRANSACTIONS OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THIS CURRENT REPORT. ANY REPRESENTATION TO THE CONTRARY CONSTITUTES A CRIMINAL OFFENSE. 

 

Cautionary Note Regarding Forward-Looking Information

 

This Current Report may contain forward-looking statements concerning HeartSciences, Fortitude and the Proposed Transaction and other matters. These forward-looking statements generally can be identified by the use of words such as “aim,” “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “potential,” “target,” “objective,” “intend,” and other words of similar meaning, but the absence of these words does not mean that a statement is not forward-looking. All statements HeartSciences and/or Fortitude make in communications that do not relate to matters of historical fact should be considered forward-looking statements.

  

These forward-looking statements are based on management’s current expectations and assumptions as of the date of such communication and are subject to a number of known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such statements, which may include, without limitation, the following: the risk that the Proposed Transaction may not be completed on the anticipated timeline or at all; the failure to satisfy the conditions to the closing of the Proposed Transaction, including obtaining the requisite approval of HeartSciences’ shareholders; market, macroeconomic, or other conditions that could adversely affect either HeartSciences or Fortitude, or the combined company; risks related to the integration of the two companies and the management of a newly public company; risks relating to Fortitude’s operations and business, including the highly volatile nature of the price of Zcash and other cryptocurrencies; and risks relating to significant legal, commercial, regulatory and technical uncertainty regarding digital assets generally. Additional factors that may cause actual results to differ materially from those expressed or implied by the forward-looking statements in such communications are discussed in the Definitive Proxy Statement, HeartSciences’ 2026 Annual Report on Form 10-K, filed with the SEC on July 23, 2026, its Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2026, filed with the SEC on September 14, 2026, and its other reports filed with the SEC from time to time. Readers are cautioned not to place undue reliance on these forward-looking statements. Each of HeartSciences and Fortitude expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law. Any forward-looking statements made in such communications are made as of the date of the communication. All information provided in this Current Report is as of November 19, 2026, and the Company undertakes no duty to update this information unless required by law. 

 

2

 

 

Participants in the Solicitation

 

HeartSciences and Fortitude, their respective directors and executive officers, and certain executive officers of Digital Currency Group, Inc. (“DCG”), the parent company of Fortitude, may be deemed to be participants in the solicitation of proxies from HeartSciences’ shareholders with respect to the Proposed Transaction. Information regarding the identity of the potential participants, and their direct or indirect interests in the Proposed Transaction, by security holdings or otherwise, is set forth in the Definitive Proxy Statement and other materials that have been or may be filed with the SEC in connection with the Proposed Transaction.

 

In the ordinary course of business, Fortitude currently sells or otherwise monetizes all the digital assets that it mines, including ZEC. In addition, Fortitude and its affiliates and subsidiaries, including DCG, from time to time sell, pledge or otherwise monetize their digital asset holdings, including ZEC. The funds received from such sales, pledges, or other monetization activities are used to fund operating expenses and capital investments, as well as for other purposes, including to hedge exposures and realize investment gains.

 

No Offer or Solicitation

 

Any information contained herein is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the Proposed Transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. The Proposed Transaction will be implemented solely pursuant to the terms and conditions of the Merger Agreement, which contain the full terms and conditions of the Proposed Transaction.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
1.1*   Equity Distribution Agreement, dated as of November 18, 2026, between the Company and Maxim Group LLC.
5.1*   Opinion of Foley Shechter Ablovatskiy LLP.
23.1*   Consent of Foley Shechter Ablovatskiy LLP (contained in Exhibit 5.1).
104*   Cover Page Interactive Data File (embedded within the Inline XBRL document).

  

*Filed herewith.

 

3

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  HEARTSCIENCES INC.
     
Date: November 19, 2026 By: /s/ Andrew Simpson
 

Name:

Andrew Simpson
  Title: President, Chief Executive Officer and
Chairman of the Board of Directors

 

4

 

Filing Exhibits & Attachments

6 documents

Keep reading